300601 康泰生物
2026/03 - 三个月
(K)
2025/12
(K)
2024/12
(K)
2023/12
(K)
2022/12
(K)
经营活动产生之现金流量净额(99,276)635,569603,2501,033,102545,696
投资活动产生之现金流量净额36,302(484,012)(556,688)(438,867)(2,606,304)
筹资活动产生之现金流量净额10,879(344,808)(800,758)(418,054)(464,876)
汇率变动对现金及现金等价物的影响(1,325)(959)(61)35(1,663)
现金及现金等价物净增加/(减少)(53,420)(194,210)(754,257)176,217(2,527,147)
期初现金及现金等价物余额221,860416,0691,170,326994,1093,521,256
期末现金及现金等价物余额168,439221,860416,0691,170,326994,109